Venture Life Group PLC Increased distribution of UltraDEX in Boots, UK (6319R)

TIDMVLG

RNS Number : 6319R

Venture Life Group PLC

18 June 2018

Venture Life Group plc

("Venture Life" or the "Company")

Increased distribution of UltraDEX in Boots Chemists, UK

Venture Life (AIM: VLG), the international consumer self-care company focused on developing, manufacturing and commercialising products for the self-care market, announces increased distribution in the UK with Boots for its UltraDEX range.

The Company announces that its listings of UltraDEX products with Boots in the UK will increase by 46% from July onwards, its highest recorded level in Boots, and added to all current existing listings in Boots and other stores this creates the highest level of total listings in the UK market since the brand launched 25 years ago. In addition to increasing the presence of some of the existing products, Boots will be launching both of the newly developed UltraDEX products: UltraDEX One GO(TM), and the new UltraDEX Fresh Breath Essential Kit.

UltraDEX One GO(TM), which also recently launched in all 793 Superdrug stores, is an innovative new product that delivers the UltraDEX fresh mint mouthwash in the form of single use sachets, for convenient on-the-go use. The UltraDEX Fresh Breath Essential Kit comprises four different UltraDEX products in one package, designed to introduce the customer to a daily regimen of fresh breath and oral care.

Boots is the UK's leading pharmacy-led health and beauty retailer with around 2,500 stores nationwide. These increases in distribution will add a further 3,686 new points of distribution for UltraDEX in Boots stores from July 2018. These additions, combined with others already gained in the last 12 months in Boots and other stores mean that the UltraDEX brand now has a total of over 18,800 points of distribution in the UK, its highest level ever nationally, and a 49% increase over its position in July 2017.

In support of this launch, promotion of the new product UltraDEX One GO(TM) via above the line advertising will appear on the London Underground platform posters from mid-June and will run for two weeks.

In addition, the UltraDEX Sensitive range has been granted a patent in Canada. This new patent adds to the existing patents granted for this innovative range in eight other countries including USA, UK, Japan and Australia.

Commenting Chief Executive Officer, Jerry Randall, said: "These additional listings in Boots are a tremendous testament to the strength of the UltraDEX range in the UK and its increasingly prominent position in one of the largest pharmacy chains countrywide. These listings have resulted in a 46% increase in the UltraDEX presence in Boots. Over the last 12 months, including this increase announced today, we have seen a 49% increase in our overall UK pharmacy and retail store listings for the range, taking it to the highest level ever for the brand.

"The acceptance of both of our new products into Boots demonstrates our ability to develop new innovative lines that gain rapid acceptance in key retailers. I am delighted that we continue to deliver on the strategic objectives we set out when acquiring UltraDEX, and I am confident that we can deliver similar results with other brands. The UK is not, however, the sole focus for UltraDEX and we have now partnered the range internationally in nine countries since acquisition, including three of the four main countries in the EU. We have also widened the patent estate over the UltraDEX Sensitive range, where the patent has now been approved in Canada, meaning this patent now covers a total of nine countries worldwide. As a Company we are excited about the future of UltraDEX and the broader territories we can continue to target with this product range."

For further information please contact:

 
                                                                                  +44 (0) 1344 
 Venture Life Group PLC                                                                 742870 
 Jerry Randall, Chief Executive Officer 
 Adrian Crockett, Chief Financial Officer 
 
 
 Northland Capital Partners Limited (Nominated Adviser                         [phone] 
  and Joint Broker)                                                                       6625 
 Matthew Johnson / Edward Hutton (Corporate Finance) 
 John Howes / Vadim Alexandre (Corporate Broking) 
 
 
                                                                               [phone] 
 Turner Pope Investments (TPI) Ltd (Joint Broker)                                         4120 
 James Pope / Ben Turner 
 
 
 Walbrook PR                                              [e-mail] or + 
                                                           44 (0) 20 7933 8780 
 Anna Dunphy /Paul McManus                                 [phone] / +44 (0) 7980 
                                                                                       541 893 
 
 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCKDLBFVQFLBBL

(END) Dow Jones Newswires

June 18, 2018 02:00 ET (06:00 GMT)